The Gemini Brief – Investment Deep Dives

Investment Research Analysis: Surgical Science Sweden AB (SUS.ST)

All investment deep dives on this site have been written by Google Gemini with light human editing. Nothing on this site constitutes investment advise. All materials on this site are for informational purposes only.

The Gemini Brief - Investment Deep Dives
The Gemini Brief – Investment Deep Dives
Investment Research Analysis: Surgical Science Sweden AB (SUS.ST)
Loading
/

Executive Summary

This report provides an in-depth analysis of Surgical Science Sweden AB (SUS.ST), the global market leader in virtual reality (VR) simulators for medical training. Through a disciplined and aggressive acquisition strategy, the company has established a dominant, near-monopolistic position in the high-growth niche of robotic surgery simulation. This strategic roll-up of key competitors has created a formidable competitive moat, underpinned by proprietary technology, deep integration with major medical device manufacturers, and extensive clinical validation.

The company’s business model is bifurcated into two segments: “Educational Products,” which sells turnkey simulators to healthcare institutions, and “Industry/OEM,” which licenses high-margin software to medical device companies. The latter represents the core long-term value driver, providing a “picks and shovels” investment exposure to the secular growth of the robotic surgery market. A pivotal strategic development is the new subscription-based agreement with its largest customer, Intuitive Surgical, for its next-generation da Vinci 5 platform, which will significantly enhance the quality and predictability of recurring revenues starting in 2025.1 Furthermore, the recent acquisition of Intelligent Ultrasound expands the company’s market leadership into the adjacent and sizable ultrasound simulation vertical, demonstrating a repeatable playbook for growth.1

From a financial perspective, Surgical Science maintains a pristine, net-cash balance sheet, providing significant optionality for further value-accretive M&A. After a period of explosive, acquisition-fueled growth in 2021-2022, top-line performance moderated, with flat revenue in fiscal year 2024.4 This was followed by a volatile first half of 2025, which saw a strong first quarter offset by a weak second quarter impacted by delayed orders and significant negative currency effects.2

Key risks to the investment case include the cyclicality of the Educational Products segment, which is sensitive to hospital capital expenditure budgets and macroeconomic conditions. The company’s valuation commands a significant premium to peers, reflecting high expectations for sustained growth and margin expansion, leaving it vulnerable to execution missteps or a broader market de-rating. Finally, the integration of multiple large acquisitions carries inherent operational risk that must be carefully managed.

The Medical Simulation Market – A Secular Growth Story

Market Landscape and Dynamics

Surgical Science operates within the rapidly expanding healthcare simulation market. This market is propelled by powerful, long-term secular trends that are fundamentally altering how medical professionals are trained. Market research reports project robust double-digit growth, though estimates vary based on scope. The broader “Healthcare Simulation Market” is forecasted to grow from approximately $3.5 billion in 2025 to $12.9 billion by 2034, representing a compound annual growth rate (CAGR) of 15.54%.8 The more specific “Surgical Simulation Market” was valued at around $554 million in 2024 and is projected to reach approximately $1.4 billion by 2033, a CAGR of 10.3%.9 A separate analysis projects a more aggressive 16.4% CAGR for this sub-segment, reaching $1.1 billion by 2030.10 While the precise growth figures differ, the consistent projection of strong, double-digit expansion across multiple independent sources confirms a robustly growing addressable market.

This growth is underpinned by several key drivers:

  • The Shift to Minimally Invasive and Robotic Surgery: The increasing adoption of complex procedures like laparoscopic and robotic-assisted surgeries necessitates specialized training that cannot be safely or efficiently conducted on live patients.9 The surgical robotics market itself is a massive tailwind, expected to grow at an 8.12% CAGR to reach $134.3 billion by 2030.11 Simulation is a critical enabler of this transition.
  • Focus on Patient Safety and Error Reduction: A primary driver for the adoption of simulation is the global healthcare imperative to improve patient outcomes and reduce medical errors. Simulation provides a risk-free environment for surgeons to practice procedures, refine psychomotor skills, and improve instrument handling before entering the operating room.8
  • Global Surgeon Shortage: Simulation-based training can accelerate and standardize the education of new surgeons, helping to address a worldwide shortage of qualified professionals, particularly in low- and middle-income countries (LMICs) where an estimated 5 billion people lack access to safe surgical care.9
  • Technological Advancements: The increasing sophistication of simulation technology, including the integration of virtual reality (VR), augmented reality (AR), artificial intelligence (AI), and haptic feedback, is making training more realistic, immersive, and effective, thereby driving wider adoption.9

Geographically, North America is the dominant market, accounting for over 40% of the global share due to its advanced healthcare infrastructure, high technology adoption rates, and strong government support for simulation-based training.8 However, the Asia-Pacific region is identified as the fastest-growing market, driven by rising healthcare investments and a growing demand for skilled surgeons.8

Industry Structure and Competitive Forces

The surgical simulation market is characterized by significant barriers to entry, which protect incumbent players like Surgical Science. These barriers include:

  • Technological and Scientific Expertise: Developing realistic, physics-based simulation software that accurately models instrument-tissue interactions is a highly complex, multidisciplinary challenge requiring deep expertise in software engineering, physics, and medicine.
  • Clinical Validation and Credibility: Gaining acceptance from the discerning medical community is a long and arduous process. It requires extensive, peer-reviewed validation studies to prove that skills acquired in the simulated environment translate to improved performance in the operating room. Surgical Science frequently highlights the more than 400 validation studies that support its products as a key differentiator.1
  • High Switching Costs and Customer Relationships: The most formidable barrier exists within the Industry/OEM segment. Once a simulation solution is deeply integrated into a medical device manufacturer’s platform, incorporated into its official training curriculum, and referenced in regulatory filings (e.g., with the FDA), it becomes exceedingly difficult, costly, and time-consuming to replace.15 This creates a very “sticky” customer relationship and a predictable, long-term revenue stream.

The market can be segmented by medical specialty, where orthopedic surgery currently holds the largest share, and by technology, where VR and 3D printing are key modalities.10 Surgical Science is positioned as the clear leader in the VR-based procedural simulation segment, particularly for the high-growth areas of general, endovascular, and robotic surgery.16

Surgical Science – Business Model and Strategic Positioning

Corporate Overview and Segments

Surgical Science’s operations are structured into two distinct business segments, each with a different business model, customer base, and margin profile.3

  1. Educational Products: This segment involves the development, manufacturing, and sale of turnkey VR simulators directly to end-users. These customers are typically teaching hospitals, university medical centers, clinics, and other medical training facilities.1 The revenue from this segment is primarily generated from one-time sales of hardware and software, supplemented by a smaller, recurring stream from service and support contracts. This business is subject to the capital budget cycles of healthcare institutions and can exhibit significant quarterly volatility, or “lumpiness,” often tied to the timing of large tenders.3
  2. Industry/OEM: This segment is the company’s strategic core and primary long-term value driver. It focuses on licensing customized simulation software and technology to medical device companies. The main customers are the world’s leading robotic surgery manufacturers, including Intuitive Surgical, Johnson & Johnson, and Medtronic.15 This model allows Surgical Science to embed its technology directly into its partners’ ecosystems, effectively making it an integral component of their product offering and training programs.

The two segments have a clear symbiotic relationship. The wide distribution of simulators through the Educational Products segment establishes Surgical Science’s brand and technological credibility within the academic medical community. The extensive use of these simulators in research generates the hundreds of validation studies that the company leverages as a key competitive advantage. This academic validation and brand recognition, in turn, strengthens its position when negotiating high-margin, long-term licensing contracts with major industry players in the OEM segment. The high-margin cash flows from the OEM business are then reinvested into R&D, benefiting both segments and creating a virtuous cycle of innovation and market leadership.

Revenue Architecture and Quality

The company’s revenue is a blend of one-time and recurring streams. The Educational Products segment is predominantly non-recurring. In contrast, the Industry/OEM segment generates a mix of revenue types:

  • Development Revenue: One-time fees for projects to customize simulation software for a partner’s specific device or surgical robot.
  • Simulator Sales: Sales of simulator hardware that are often bundled with the launch of a partner’s new robotic system.
  • License Revenue: The highest quality revenue stream. These are high-margin, recurring royalties generated from the use of Surgical Science’s software on the installed base of robotic systems. This revenue is often tied to utilization, system placements, or, increasingly, subscriptions.3

A pivotal moment for the company was the announcement in January 2025 of a new agreement with Intuitive Surgical. This agreement transitions the revenue model for Intuitive’s new da Vinci 5 surgical system to be entirely subscription-based, effective from the start of 2025.1 This marks a significant strategic shift that de-risks a key revenue stream, dramatically improves forward visibility, and increases the overall quality of earnings. This move provides a template for future OEM partnerships, signaling a transition from a component supplier to a long-term, embedded software-as-a-service (SaaS) partner, a model that typically commands a higher and more stable valuation multiple in public markets.

Global Operations and Customer Base

Surgical Science is a global company headquartered in Gothenburg, Sweden. Its operational footprint has expanded significantly through acquisitions, with key development and operational hubs now in Tel Aviv, Israel (from Simbionix), Seattle and Cleveland, US (from Mimic and Simbionix), and Cardiff, UK (from Intelligent Ultrasound).2 The company maintains a direct sales presence in the US and China and utilizes a global network of distributors to cover more than 60 markets worldwide.3

The customer base reflects the dual-segment model. The Educational Products segment serves thousands of academic and hospital clients globally.1 A recent and notable expansion of this customer base is into the military sector, highlighted by a significant SEK 52 million procurement contract with the defense ministry of a Southeast Asian country in early 2025.1 The Industry/OEM customer base is more concentrated, comprising a “who’s who” of the medical device industry, with an estimated 10-15 robotic surgery companies as key partners.19

Competitive Moat and Innovation Engine

Market Leadership Through Strategic Consolidation

Surgical Science’s current market position is the direct result of a deliberate and highly effective M&A strategy designed to consolidate the fragmented medical simulation market.1 This “roll-up” strategy has transformed the company into the undisputed global leader. The most significant acquisitions include:

  • SenseGraphics (2019): An early acquisition that brought in valuable haptics (sense of touch) technology and expertise.15
  • Mimic Technologies (2021): A landmark transaction that brought Surgical Science’s key competitor in-house. Mimic was the original simulation partner for the market leader in robotic surgery, Intuitive Surgical.15
  • Simbionix (2021): Acquired from 3D Systems, this was another transformative deal. Simbionix was a major player in its own right and its acquisition vastly expanded Surgical Science’s product portfolio into new medical specialties such as endovascular procedures, gastroenterology, and orthopedics.15
  • Intelligent Ultrasound (2025): This recent acquisition makes Surgical Science the market leader in the separate but adjacent vertical of ultrasound simulation, a large market with a significant need for user training.2

This series of acquisitions was both defensive and offensive. It removed the company’s most significant competitors, effectively creating what some analysts describe as a “quasi-monopoly” in the niche of VR simulation for robotic surgery.15 This consolidation provides Surgical Science with significant pricing power and negotiating leverage with its OEM customers, as there are few, if any, viable alternative partners with the same scale, technological prowess, and depth of clinical validation. The acquisition of Intelligent Ultrasound represents a strategic pivot, demonstrating an ambition to replicate this successful consolidation playbook in other simulation verticals, thereby diversifying the business and opening up new addressable markets.

Competitive Advantages

The company’s durable competitive advantages, or “moat,” are built on several pillars:

  • Technological Superiority: The company’s core competence is its proprietary software, particularly its physics engine that simulates realistic instrument-tissue interactions. This is a key intellectual property asset that is carefully protected.1
  • Scale and Breadth of Portfolio: Following the acquisitions, Surgical Science now offers the industry’s most comprehensive suite of simulators, covering approximately 30 products and over 150 simulated procedures across a wide range of medical specialties.14
  • Deep OEM Integration and High Switching Costs: As previously detailed, the deep, long-term integration with OEM partners’ platforms creates powerful, sticky customer relationships that are difficult for competitors to penetrate.15
  • Unmatched Clinical Validation: The extensive library of over 400 independent, peer-reviewed validation studies provides a level of clinical credibility that is a significant hurdle for any new entrant to overcome.1

Research and Development

Innovation is the lifeblood of the company, and R&D investment is a significant and ongoing priority. In the fourth quarter of 2024, R&D expenses represented 21% of net sales.3 For the full fiscal year 2024, total R&D expenses amounted to SEK 184.7 million.21 The company follows an accounting practice of capitalizing a portion of its development costs, with SEK 10.2 million in costs being activated (moved to the balance sheet as an asset) in Q4 2024.3 The R&D organization is focused on a continuous pipeline of innovation, including the launch of new training modules, such as the Pediatric Advanced Echo module in Q3 2024, and the constant expansion of procedural content and advanced instrumentation for its OEM partners.17

Financial Performance and Analysis

Historical Performance (2018-2024)

Surgical Science’s financial trajectory over the past seven years clearly illustrates its evolution from a small, emerging growth company into a scaled and profitable market leader. The transformative impact of the acquisitions of Mimic and Simbionix in 2021 is the most prominent feature of its recent history.

Revenue growth was explosive following these deals, with sales increasing by 250% in 2021 to SEK 366.8 million, followed by a 119% increase in 2022 to SEK 802.5 million.20 On an organic basis (for comparable units), sales growth in 2022 was still a very strong 34%.22 Growth then moderated significantly, with a 10% increase in 2023 to SEK 882.9 million and a flat performance in 2024, with sales of SEK 884.1 million.4 This slowdown reflects a more challenging macroeconomic environment impacting the Educational Products segment and tougher year-over-year comparisons.

Profitability has been a key strength. Gross margins have been consistently high, typically ranging from 68% to 71%, with fluctuations driven by the sales mix between high-margin software licenses and lower-margin hardware.3 The company has demonstrated strong operating leverage, with adjusted EBIT margins reaching 23.2% in 2022 and 24.2% in 2023.19

Table 1: 7-Year Financial Summary (2018-2024)
Metric (SEK M, except where noted)FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024
Net Sales65.7101.5104.8366.8802.5882.9884.1
Sales Growth (%)14.6%54.5%3.2%250.0%118.8%10.0%0.1%
Gross ProfitN/A83.688.4265.9531.3609.2601.2
Gross Margin (%)N/A82.3%84.3%72.5%66.2%69.0%68.0%
Operating Profit (EBIT)-4.115.220.056.5162.5189.2144.3
EBIT Margin (%)-6.2%15.0%19.1%15.4%20.2%21.4%16.3%
Net Profit-4.512.615.686.2188.0234.0131.6
EPS (SEK)N/AN/A0.452.033.704.592.58
Cash Flow from Operations6.955.223.239.1129.5238.3137.2
Sources:.4 Note: Gross Profit/Margin for 2018 not available in provided materials. EPS data for 2018-2019 not available.

A segmental breakdown reveals two distinct stories. The Industry/OEM segment has been the consistent growth engine, driven by the expansion of robotic surgery. License revenue, the most profitable component, grew by an impressive 50% in 2023.18 In contrast, the Educational Products segment has shown more volatility. After a very strong 2022, it saw modest growth in 2023 and then declined by 15% in 2024, impacted by a tough macroeconomic environment, a government anti-corruption campaign affecting the healthcare sector in China, and the absence of a typical year-end budget flush from hospitals.3

Table 2: Segment Revenue and Growth Breakdown (2020-H1 2025)
Metric (SEK M, except where noted)FY 2020FY 2021FY 2022FY 2023FY 2024H1 2025
Total Net Sales104.8366.8802.5882.9884.1459.8
Educational Products Revenue47.7197.4507.9518.4442.4250.7*
Educational Growth (%)N/A313.8%157.3%2.1%-14.7%N/A
Industry/OEM Revenue57.1169.4294.6364.5441.7209.1*
Industry/OEM Growth (%)N/A196.7%73.9%23.7%21.2%N/A
License RevenueN/AN/A184.5277.7271.7142.7
License Growth (%)N/AN/AN/A50.5%-2.2%9.5%**
License as % of Total SalesN/AN/A23.0%31.4%30.7%31.0%
*Sources:.3 Note: H1 2025 segment breakdown not explicitly provided; figures represent total sales for Q1 and Q2. *H1 2025 license growth is vs H1 2024.

Recent Performance and Challenges (H1 2025)

The first half of 2025 presented a volatile and challenging picture. The first quarter was very strong, with net sales growing 33% year-over-year to SEK 250.7 million. This was driven by a 55% surge in the Educational Products segment, which included SEK 18.3 million in acquired revenue from Intelligent Ultrasound.2 However, reported operating profit was suppressed by SEK 26.5 million in one-time acquisition and restructuring costs related to the deal.2

The second quarter brought a sharp reversal. The company pre-announced weak sales and negative currency effects.1 The final Q2 report confirmed a 2% decline in net sales to SEK 209.2 million (a 12% decline for comparable units). The company swung to an operating loss of SEK -22.4 million, which was heavily impacted by a SEK 24.7 million negative currency revaluation effect.6 Management attributed the weak top-line performance to delays in customer order placements, which resulted in the order book for simulators growing by approximately SEK 30 million during the quarter.6

Balance Sheet and Cash Flow

Surgical Science maintains an exceptionally strong and liquid balance sheet, which is a key strategic asset. The company has a significant net cash position, which stood at SEK 732.7 million at the end of fiscal year 2024.4 As of the most recent reporting date, June 30, 2025, cash and cash equivalents amounted to SEK 610.2 million.6 The company has minimal debt, and its equity-to-assets ratio is very high, consistently in the 88% to 92% range, indicating a very low-risk capital structure.23

Cash flow from operating activities has historically been robust, totaling SEK 238.3 million in 2023 before declining to SEK 137.2 million in 2024.4 The first half of 2025 saw weaker operating cash flow of SEK 11.3 million, impacted by the one-time acquisition costs and adverse movements in working capital.6

Strategic Outlook and Growth Levers

Organic Growth Prospects

The company’s future growth is expected to be driven by organic expansion in both of its core segments.

  • Industry/OEM: This segment is poised for continued strong growth. The primary driver will be the ongoing global rollout of new robotic surgery platforms by Surgical Science’s partners. Each new system launch typically generates a stream of development fees, initial simulator sales, and, most importantly, long-term, high-margin license revenues.28 Furthermore, as the installed base of surgical robots grows and procedure volumes increase, the utilization-based component of license revenue is also expected to grow steadily.18
  • Educational Products: The outlook for this segment is one of gradual recovery. Management has expressed “cautious optimism”.3 Growth is anticipated to come from the launch of new products and training modules, further penetration into new customer segments such as military medical training 1, and a normalization of capital spending by hospitals and teaching institutions as macroeconomic pressures ease.5

M&A Strategy and Capital Allocation

Growth through acquisition remains a core pillar of the company’s strategy. Management has explicitly stated that “supplementary acquisitions” may be necessary to achieve its long-term financial targets.29 The company’s strong net cash position and robust balance sheet provide ample firepower to continue executing this proven M&A playbook. The recent acquisition of Intelligent Ultrasound demonstrates a clear intent to replicate its consolidation strategy in new, attractive simulation verticals.

The company’s capital allocation priorities are clearly focused on growth. The primary uses of cash are reinvestment in organic growth through R&D and funding strategic M&A. In line with this growth-oriented strategy, Surgical Science does not currently pay a dividend, instead choosing to retain all earnings to finance its expansion.30

Management and Governance

The company’s leadership team has recently undergone a strategic reorganization. In late 2024, the management team was streamlined from eight to five members to create clearer ownership and facilitate quicker decision-making.5 Tom Englund was appointed CEO in October 2024, bringing experience from other fast-growing technology companies, while CFO Anna Ahlberg has been with the company since 2018.32 The Board of Directors includes members with very long tenure (some since 2005) and significant personal shareholdings, which suggests a strong alignment of interests with long-term shareholders.32

From a governance perspective, it is important to note that Surgical Science’s shares are traded on the Nasdaq First North Growth Market, which is a multilateral trading facility and not a fully regulated market. As such, the company is not obligated to comply with the formal Swedish Corporate Governance Code and has not voluntarily committed to doing so.32

Financial Targets

Management has previously communicated long-term financial targets of reaching SEK 1.5 billion in sales by 2026, with a 40% adjusted EBIT margin.23 Given the flat revenue performance in 2024 and the headwinds experienced in H1 2025, achieving the SEK 1.5 billion sales target organically appears increasingly challenging. From the FY2024 base of SEK 884 million, a compound annual growth rate of approximately 19% would be required through 2025 and 2026. This suggests that achieving the target will likely depend on further M&A activity. In recognition of the company’s evolution, management is currently conducting a strategic review and plans to communicate new financial targets for the period beyond 2026 in the autumn of 2025.28 This strategic review, combined with the recent management reorganization, suggests the company is at an inflection point, shifting from a phase of rapid acquisition to a focus on integration, operational efficiency, and setting a new long-term strategic course.

Risk Assessment and Potential Headwinds

An investment in Surgical Science carries several risks that must be considered. These risks, as identified by the company and through this analysis, span business, financial, and market-specific categories.

Business and Operational Risks

  • Customer Concentration: The company has a significant reliance on the Industry/OEM segment, and within that, a high degree of dependence on the commercial success of its largest customers, most notably Intuitive Surgical. Any slowdown in the sales of their robotic systems, delays in new product launches, or a decision by a key partner to develop simulation technology in-house would have a direct and material negative impact on Surgical Science’s high-margin license revenue.14
  • M&A Integration Risk: The company’s rapid growth has been fueled by a series of large and complex acquisitions. There is an inherent risk that the integration of these disparate businesses—including their technologies, personnel, and cultures—may fail to realize the expected synergies or could lead to operational disruptions and unforeseen costs.14
  • Technological Disruption and Competition: The medical technology landscape is characterized by rapid innovation. While Surgical Science is the current leader, it remains vulnerable to the emergence of new, disruptive training technologies or the possibility that a competitor could develop a superior simulation platform that gains traction with customers.14
  • Intellectual Property Protection: The company’s proprietary physics engine and simulation software are its most valuable assets. A failure to adequately protect this core intellectual property from infringement or theft would severely undermine its competitive position.14

Financial and Market Risks

  • Macroeconomic Sensitivity: The Educational Products segment is directly exposed to the cyclicality of hospital and government spending. During periods of economic downturn, healthcare capital budgets are often constrained, which can lead to delayed or canceled purchases of simulators, as was evident in the weaker performance of this segment in 2023 and 2024.14
  • Currency Exposure: As a global company that reports in Swedish Krona (SEK) but generates a significant portion of its revenues and incurs costs in other currencies, primarily the US Dollar (USD) and Euro (EUR), Surgical Science is exposed to foreign exchange rate fluctuations. This risk was starkly illustrated in the second quarter of 2025, when a negative currency revaluation effect of SEK 24.7 million was a primary driver of the reported operating loss.6
  • Geopolitical Risks: The company has a significant and strategically important operational presence in Israel, with 146 employees as of Q1 2025.28 This exposes the business to potential disruptions from geopolitical instability in the Middle East. While management stated in late 2023 that the situation had not impacted deliveries or deadlines, it remains a key risk factor.18 The company is also actively monitoring potential changes to US trade policy and tariffs, although it currently believes that existing free trade agreements will mitigate most of the direct impact.5

Valuation Context

Valuation Multiples Analysis

Surgical Science’s valuation reflects its status as a high-growth, market-leading technology company with a strong competitive moat. As of August 2025, the company’s valuation multiples are significant. The stock trades at an enterprise value (EV) to last-twelve-months (LTM) revenue multiple of 4.5x and an EV/LTM EBITDA multiple of 20.1x.35 On a forward-looking basis, the price-to-earnings (P/E) ratio is estimated at 25.4x.36 These multiples suggest that the market has high expectations for the company’s future growth in both revenue and profitability. A news report from August 2025 noted a trailing P/E ratio of 36.2x, indicating that some multiple compression has occurred recently, likely in response to the weaker Q2 2025 results and the flat performance in 2024.37

Peer Comparison

Direct publicly-traded competitors are scarce due to Surgical Science’s successful market consolidation strategy. Therefore, a relevant peer group includes broader medical technology companies and other players in the healthcare simulation space. This comparison provides context for Surgical Science’s premium valuation.

Table 3: Valuation Multiples – Peer and Historical Comparison
CompanyTickerMarket CapEV/LTM SalesEV/LTM EBITDALTM P/ELTM Rev GrowthLTM EBITDA Margin
Surgical ScienceSUS.STSEK 5.1B4.8x23.4x55.3x~0%18.3%
CAE Inc.CAE.TOCAD 12.0B3.2x16.1x28.6x~10%*20.0%
CellaVision ABCEVI.STSEK 7.0B9.9x35.0x44.0x3.5%28.3%
Elekta ABEKTA-B.STSEK 30.2B1.6x10.5x24.3x~5%*15.2%
*Sources:.21 Multiples are based on most recent available data as of August 2025 and may vary slightly between sources. Market caps are approximate.Growth rates are estimates based on recent performance.

The data shows that Surgical Science trades at a notable premium to its largest simulation peer, CAE Inc., on an EV/EBITDA basis (23.4x vs. 16.1x). This premium can be attributed to several factors, including Surgical Science’s higher-margin, software-centric business model, its monopolistic position in the robotic surgery niche, and its stronger long-term growth prospects tied to that specific end market. Compared to other Swedish medtech companies like Elekta, the premium is even more pronounced.

Valuation Narrative and Drivers

The premium valuation is underpinned by the company’s strong qualitative attributes: its market leadership, high and growing proportion of recurring revenue, strong secular tailwinds from the robotic surgery market, and formidable barriers to entry. Analyst consensus estimates project robust future earnings growth, with forecasts suggesting 47% annual EPS growth over the next three years, far outpacing the broader market’s expected 17% growth.37 This superior growth profile is a key justification for the high P/E ratio.

However, the valuation is also sensitive to potential negative catalysts. A failure to meet these high growth expectations, significant margin compression from a less favorable sales mix (e.g., the integration of the lower-margin Intelligent Ultrasound business 28), or the emergence of a credible competitor could all lead to a significant de-rating of the company’s valuation multiples. Conversely, a successful execution of the SaaS transition across more OEM partners and continued value-accretive M&A could provide catalysts for further positive re-rating over the long term.

Works cited

  1. Investor Relations – Surgical Science, accessed August 29, 2025, https://surgicalscience.com/investor-relations/
  2. Interim report January – March 2025: Strong growth despite …, accessed August 29, 2025, https://surgicalscience.com/mfn_news/interim-report-january-march-2025-strong-growth-despite-macroeconomic-uncertainties/
  3. Surgical Science Presentation of Year-end Report 2024 February 19, 2025, accessed August 29, 2025, https://surgicalscience.com/wp-content/uploads/2025/02/SuS_presQ4_250219.pdf
  4. Year-end report 2024: STRONG END TO THE YEAR – Surgical Science, accessed August 29, 2025, https://surgicalscience.com/mfn_news/year-end-report-2024-strong-end-to-the-year/
  5. YEAR-END REPORT 2024 – MFN.se, accessed August 29, 2025, https://storage.mfn.se/a03b6ffb-1233-4467-a89c-e92c7e01d712/250219-q42024-eng.pdf
  6. Interim report January–June 2025: Weak sales and significant …, accessed August 29, 2025, https://surgicalscience.com/mfn_news/interim-report-january-june-2025-weak-sales-and-significant-currency-effects-weighed-on-the-result/
  7. Q2 2025 Surgical Science Sweden AB Earnings Call Transcript – GuruFocus, accessed August 29, 2025, https://www.gurufocus.com/news/3074733/q2-2025-surgical-science-sweden-ab-earnings-call-transcript
  8. Healthcare Simulation Market Forecast 2025 to 2034 Key Players, Regional Insights, and Growth Drivers, accessed August 29, 2025, https://www.towardshealthcare.com/insights/healthcare-simulation-market-sizing
  9. Surgical Simulation Market Size, Top Share, Global Trends | Industry Report, 2033, accessed August 29, 2025, https://straitsresearch.com/report/surgical-simulation-market
  10. Surgical Simulation Market Size, Share | Industry Report 2030 – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/surgical-simulation-market-report
  11. Surgical Robots Market – Global Industry Analysis and Forecast (2024-2030), accessed August 29, 2025, https://www.maximizemarketresearch.com/market-report/global-surgical-robots-market/22528/
  12. Year-end report 2023: STRONG LICENSE REVENUE, WEAKER SIMULATOR SALES, accessed August 29, 2025, https://surgicalscience.com/mfn_news/year-end-report-2023-strong-license-revenue-weaker-simulator-sales/
  13. Healthcare Simulation Market worth $7.23 billion by 2030 – MarketsandMarkets, accessed August 29, 2025, https://www.marketsandmarkets.com/PressReleases/healthcare-medical-simulation.asp
  14. Surgical Science Annual report 2024 – MFN.se, accessed August 29, 2025, https://storage.mfn.se/e94da8c5-4e20-4337-917e-9727df2b41ba/surgical-science-annual-report-2024.pdf
  15. Surgical Science Sweden Profile – Redeye, accessed August 29, 2025, https://www.redeye.se/company/surgical-science/profile
  16. Simbionix® simulators by Surgical Science, accessed August 29, 2025, https://surgicalscience.com/simbionix/
  17. Surgical Science Presentation of Interim Report Q3 November 14, 2024, accessed August 29, 2025, https://surgicalscience.com/wp-content/uploads/2024/11/SuS_presQ3_241114.pdf
  18. Surgical Science Presentation of Year-end report 2023 February 21, 2024, accessed August 29, 2025, https://surgicalscience.com/wp-content/uploads/2024/02/SuS_presQ4_240221.pdf
  19. Surgical Science | Annual Report 2022, accessed August 29, 2025, https://surgicalscience.com/wp-content/uploads/2023/09/sus-ar22-en-1.pdf
  20. ANNUAL REPORT 2021 | Surgical Science, accessed August 29, 2025, https://surgicalscience.com/wp-content/uploads/2022/11/SuS-AR-21_ENG.pdf
  21. Research Development – Surgical Science Sweden AB (STO:SUS) – Alpha Spread, accessed August 29, 2025, https://www.alphaspread.com/security/sto/sus/financials/income-statement/research-development
  22. Year-end report 2022: STRONG END TO AN AMAZING YEAR – Surgical Science, accessed August 29, 2025, https://surgicalscience.com/mfn_news/year-end-report-2022-strong-end-to-an-amazing-year/
  23. year-end report 2023 – surgical science sweden ab (publ) – MFN.se, accessed August 29, 2025, https://storage.mfn.se/9af7b253-f899-406b-9219-79171cab38b1/240221-q42023-eng.pdf
  24. ÅRSREDOVISNING 2018 – Surgical Science, accessed August 29, 2025, https://surgicalscience.com/wp-content/uploads/2023/05/SuS-AR-18_190415.pdf
  25. Årsredovisning 2019 | Surgical Science, accessed August 29, 2025, https://surgicalscience.com/wp-content/uploads/2023/05/Arsredovisning-2019.pdf
  26. YEAR-END REPORT 2020 – Cision, accessed August 29, 2025, https://mb.cision.com/Main/15619/3284153/1370951.pdf
  27. ANNUAL REPORT 2023 | Surgical Science, accessed August 29, 2025, https://surgicalscience.com/wp-content/uploads/2024/04/Annual-report-2023.pdf
  28. Interim report January–March 2025 – MFN.se, accessed August 29, 2025, https://storage.mfn.se/5b49d94e-caf5-4968-a209-8d32fa1afa5a/delarsrapport-q1-sus-2025-en.pdf
  29. New financial goals for Surgical Science, accessed August 29, 2025, https://surgicalscience.com/mfn_news/new-financial-goals-for-surgical-science/
  30. Annual General Meeting SuS – 2023 – Surgical Science, accessed August 29, 2025, https://surgicalscience.com/investor-relations/annual-general-meeting-sus-2023/
  31. Report from the Annual General Meeting of Surgical Science Sweden AB (publ), accessed August 29, 2025, https://surgicalscience.com/mfn_news/report-from-the-annual-general-meeting-of-surgical-science-sweden-ab-publ-5/
  32. Corporate Governance – Surgical Science, accessed August 29, 2025, https://surgicalscience.com/corporate-governance/
  33. SUS Investor Relations – Surgical Science Sweden AB – Alpha Spread, accessed August 29, 2025, https://www.alphaspread.com/security/sto/sus/investor-relations
  34. Surgical Science Sweden AB (publ) (SUS) Leadership & Management Team Analysis, accessed August 29, 2025, https://simplywall.st/stocks/se/healthcare/sto-sus/surgical-science-sweden-shares/management
  35. Surgical Science – Public Comps and Valuation Multiples, accessed August 29, 2025, https://multiples.vc/public-comps/surgical-science-valuation-multiples
  36. Surgical Science Sweden AB (STO:SUS) Statistics & Valuation Metrics – Stock Analysis, accessed August 29, 2025, https://stockanalysis.com/quote/sto/SUS/statistics/
  37. What You Can Learn From Surgical Science Sweden AB (publ)’s (STO:SUS) P/E After Its 32% Share Price Crash, accessed August 29, 2025, https://simplywall.st/stocks/se/healthcare/sto-sus/surgical-science-sweden-shares/news/what-you-can-learn-from-surgical-science-sweden-ab-publs-sto
  38. Surgical Science Sweden (OM:SUS) – Stock Analysis – Simply Wall St, accessed August 29, 2025, https://simplywall.st/stocks/se/healthcare/sto-sus/surgical-science-sweden-shares
  39. Surgical Science Sweden AB (publ) (SUSRF) Related Stock Growth, Competitive Growth | Seeking Alpha, accessed August 29, 2025, https://seekingalpha.com/symbol/SUSRF/peers/related-stocks/growth
  40. EV / EBITDA For CAE Inc (CAE) – Finbox, accessed August 29, 2025, https://finbox.com/NYSE:CAE/explorer/ev_to_ebitda_ltm/
  41. CAE Inc. (TSX:CAE) Statistics & Valuation Metrics – Stock Analysis, accessed August 29, 2025, https://stockanalysis.com/quote/tsx/CAE/statistics/
  42. CAE Intrinsic Valuation and Fundamental Analysis – CAE Inc – Alpha Spread, accessed August 29, 2025, https://www.alphaspread.com/security/tsx/cae/summary